Professor Simi Ali
Professor of Immunobiology
- Email: email@example.com
- Telephone: +44 (0) 191 208 7158
- Personal Website: http://www.ncl.ac.uk/biomedicine/research/groups/appliedimmuno.htm
- Address: Institute of Cellular Medicine
3rd Floor William Leech Building
Roles and Responsibilities
I have held senior management responsibilities within the University and Institute and also serve on external Scientific Committee. For example:
Member of Faculty Promotion Committee (2015-18)
Mentor for Faculty Future's Programme (2014-present)
Member of FMS Equality & Fairness (Athena Swan) Steering Group (2013-present)
Member of FMS Early Career Research Committee (2014-present)
Member of MRes exam committee. (2007-present)
Institute of Cellular Medicine Committees
Chair Institute Athena SWAN Steering Group (May 2012-present)
University appointed Governor for Royal Grammar School (2010-present).
Member of Northern Counties Kidney Research Fund Scientific Committee (2011-present)
Panel Member for National Athena SWAN (Equality Challenge Unit)
Member of Institute of Cellular Medicine Executive Board (2012-15)
Member of University Senate (2009-2012).
ICM Post-graduate coordinator (2004-2011).
Chair Institute Postgraduate Committee (2008-2011).
Member of Graduate School Committee.(2004-2011)
Member of Institute Management Committee. (2008-2011)
1984 BSc Chemistry (1st Class Honours). AMU, Aligarh, India.
1986 MSc Biochemistry (1st Class). AMU, Aligarh, India.
1991 PhD Biochemistry. Central Drug Research Institute, Lucknow, India
1990-91 Commonwealth Post-doctoral Fellow in Molecular Biology at UMIST, Manchester, UK.
1992-95 Post-doctoral Fellow at Department of Biological Sciences, University of Newcastle upon Tyne. Project funded by Biotechnology and Biological Sciences Research Council.
1995 (Sept) Lecturer in Molecular Biology of Organ Transplantation, Department of Surgery, University of Newcastle Upon Tyne. (Funded by Northern Counties Kidney Research Fund).
1999(Sept) Lecturer B, Department of Surgery (HEFCE funded)
2002 Senior Lecturer
2007 Reader in Immunobiology
2011 Professor of Molecular Immunology
British Society of Immunology, British Transplantation Society
Honours and Awards
1. Award for Excellence in Science technology and Engineering (Muslim News)-Presented by: Rt Hon Ed Miliband MP, Leader of the Labour Party, London, March 2015.
2. Exhibition at Hatton's gallery on Inspirational Women of North East from 3rd October -20th December, 2013-I have been used as one of the examples. http://www.iwne.org/
3. I was awarded special recognition award by Roche Organ Transplantation research Fund for my contribution to research in Transplantation (cash award of 1000 Swiss Francs)-April 2011.
4. Member of Northern Counties Kidney Research Fund Scientific Sub-Committee.
5. Member of panel for ICM Grant Review System.
6.Regularly review grants for MRC, BBSRC, Cancer Research UK, British Heart Foundation, Wellcome, Asthma UK Foundation and Singapore Biomedical Research Council.
7.Editorial Board Member for “
· Mediators of Inflammation
· Journal of Glycobiology
· Frontiers in Alloimmunity and Transplantation
6. Institute of Cellular Medicine was awarded Athena SWAN silver award-June 2013 (I was the academic lead for this application).
My main area of research is studying the immunobiological processes that result in tissue damage, which has applications in transplantation immunobiology and cancer immunotherapy. This work is focused largely on the regulatory interactions between T lymphocytes and endothelial and epithelial cells. Within this area, specific interests include the role of cc chemokines in inflammation, their interaction with cell surface glycosaminoglycans and signal transduction mechanisms mediated by them.
My work so far has helped in clearly defining the role of chemokines in inflammation with particular relevance to transplantation. It has also demonstrated that in addition to binding to their specific G-protein coupled receptors, chemokines also interact with cell surface glycosaminoglycans (GAGs) (J Biol Chem: 276, 1721, 2000 ). My subsequent work has convincingly shown that this chemokine-GAG interaction is essential for in vivo activity of these cytokines ( American Journal of Transplantation, 2010, 10:47-58, PNAS, 2012). In addition I have shown the changes in cell surface heparan sulphate patterns in response to inflammation which in turn regulates cytokine function (Journal of Biological Chemistry, 2014). This suggests that formation of glycosaminoglycan-stabilised cytokine concentration gradient play an important role in modulating the biological activity of the cytokine.
My other major interest has been examining the role of chemokine-chemokine receptor interaction in breast cancer metastasis in collaboration with Professor TWJ Lennard. We have established an in vivo model of Breast cancer metastasis and have shown significantly reduced metastasis in animals treated either with heparin or non-glycosaminoglycan binding chemokines.
1) Chemokines regulate cardiac allograft rejection by stimulating migration of inflammatory cells. Oxidative stress is a key feature during ischaemia-reperfusion injury (IRI) resulting in induction and post-translational modification of chemokines. This can lead to changes in their biological activity and also alter detection, potentially limiting the biological relevance of some proteomic biomarkers. Data in our group has shown that peroxynitrite, a reactive nitrogen species (RNS) generated during IRI, can cause nitration of chemokines. In this project we will determine how tissue stress effects the production of the chemokines and investigate which chemokines undergo RNS associated modification and its effect on their biological activity in vitro and in vivo. Determination of the presence and function of nitrated-chemokines in transplant patients may offer therapeutic opportunities for prolongation of graft survival. (funded by British Heart Foundation)
2) Organ transplantation is the treatment of choice for many patients with end-stage diseases. Waiting lists are lengthening but the supply of donor organs has not expanded to meet this demand. Chronic rejection resulting in late loss of graft function now represents the greatest clinical challenge, with many patients rejoining the waiting list years after an initial transplant operation. Indeed, as many as a third of patients joining the kidney transplant waiting list have already chronically rejected one or more previous transplants. Preventing this form of graft loss would have a huge socio-economic impact for patients and transplant medicine. Basic research performed by our group and others has defined this problem but has failed to provide any clinically useful solution. We now believe this solution lies at the interface between basic science and translational medicine, with necessary involvement of the private sector. The POSAT scheme will address this by training a cohort of 4 early stage researchers to function at this dynamic interface in order to address specific problems which contribute to chronic graft failure. This programme will meet two specific objectives: development of methods to reduce organ inflammation immediately after transplantation (thereby preserving long-term graft function), and identification of biomarkers which allow transplant patients to be stratified allowing individualized drug treatment. These complementary objectives will be addressed by allocation of a trainee-specific project to each of the 4 early stage researchers. Although based at Newcastle University, each trainee will spend significant periods working with carefully selected private sector partners and academics at another university in the NorthEast of England. This scheme will produce well qualified translational research scientists who will further our understanding of treatment modalities directed at the Prolongation of Organ Survival After Transplantation.(Funded by Marie Curie — Initial Training Networks (ITN), Innovative Doctoral Programmes (IDP))
I currently supervise Post-doctoral Fellow, Research associate, PhD students, MD students and technician. I regularly take Mres and undergraduate project students.
I referee grants regularly from British Heart Foundation, BBSRC etc and have been appointed as examiner (internal/external) regularly for PhD as well as MD thesis. Furthermore, I am also involved in the annual assessment of PhD and MD students within the School/Faculty.
18 successful submission for PhD during last 10 years
I currently supervise 2 Post-doctoral Fellow, 7 PhD students, 1 MD, 1 Technician, Mres project student and regularly take project students from Institute of Cell and Molecular Biosciences. My both the recent Mres project students went on to secure Distinction in their projects.
I was awarded special recognition award by Roche Organ Transplantation research Fund for my contribution to research in Transplantation (cash award of 1000 Swiss Francs)-April 2011.
I am member of the organising team and chaired the Transplantation session for British Society of Immunology Summer School, held at Newcastle in July 2013.
Scientific Panels: a) Member of Northern Counties Kidney Research Fund Scientific Sub-Committee.
Oral Presentation at British Society of Transplantation, March (2013).
Transplantomics (Cambridge) April, 2013.
Invited talk at Aberdeen Medical School (May 2013).
Oral presentation at International HLA and Immunogenetics Conference, Liverpool, 2nd June’2012.
Oral presentation at American Transplant Congress, June 2012, Boston, USA.
Session chair for therapeutic tolerance workshop, 26-29th June, 2013, Newcastle University.
I led initiative to set up Transplant Biobank at Newcastle Freeman Hospital (2012-14).
My work has been funded from various National/ International funding bodies (British Heart Foundation, Wellcome, Roche Organ Transplantation Research Fund, MRC, National Kidney Research Fund etc).
I regularly referee manuscripts for Journal of Biological Chemistry, Transplantation, Plos one, etc and am a member of BBC panel for analysis of scientific news related to transplantation/inflammation.
4 international and 14 national invited seminars ranging from presentations given to academic institutions, conferences, and scientific meetings during last 5 years.
(1992-1995): As a Post-doctoral Researcher I single-handedly established the transgenic facility at Newcastle and generated several transgenic lines of mice to address the important issue of protein trafficking. The data generated has been published in peer reviewed journals (Nature Biotechnology 11:376, 1992, Biochemical Journal, 315:857-862, 1996, Gene 202: 203-208, 1997 etc).
1990-1992: I was awarded a Commonwealth Post-doctoral Fellowship in Molecular Biology, which is given out only to five candidates every year.
1986-1990: Recipient of National scholarship by Council of Scientific and Industrial Research, India, based on a competitive exam to study for PhD.
During my tenure in Newcastle I have been successful in attracting grant income from national charities and international funding bodies. My current grants include:
- POSAT— Prolong Organ Survival After Transplantation. FP7-PEOPLE-2013-ITN. Marie Curie Actions— Initial Training Networks (ITN), Innovative Doctoral Programmes (IDP) (2014-2017)
Coordinator: Simi Ali: 1,174,367.26 Euro.
- Modulation of Wound healing post Myocardial Infarction (PI SA). Awarded grant from Newcastle special Trustees to generate pilot data (2014-15) (£47,000).
- Post-translation modification of Chemokines during heart transplantation: Implications for their biological function.(Ali, S & Kirby JA) (2015-18), British Heart Foundation, £105,343)
Collaborative links with Industry:
Cellix, Dublin, microfluidics drug screening tool for examination of adhesion and migration of leukocytes.
Qiagen, Manchester, leading provider of sample and assay technologies.
Alamac, Edinburgh, specializes in long chain peptide synthesis.
• PCT/GB2005/002184 (Filing date: 3rd June 2005), non-GAG binding chemokine receptor agonists CCL7, which may be used to treat inflammatory conditions. (Ali S and Kirby JA).
.Inventor on European patent application 07450189.1-2406, SDF-1 based glycosaminoglycan antagonists and method of using same. (Kungl A, Werner, I, Slingsby, J, Ali, S, Kirby, JA).
Mres Applied Immunobiology of Human Disease (20 credits) MMB8015, Strand leader: I designed this multi-disciplinary module, drawing upon the specialized expertise and research strengths of academic staff in Medical faculty in 2006. I stepped down from being a Module leader (2009/10) but I have retained the position of strand leader. This involves allocating the project to students stranding in AIB, nominating both external and internal examiners for the dissertation. Additionally, I give two lectures on the AIB module and also assess the oral presentations. (Marking includes essay, exam scripts and Mres thesis)
PGY805 MRes in Medical & Molecular Biosciences (Transplantation Sciences) (Lecture 2h, Course work/tutorial 5h)
BMS 3007 RESEARCH IN BIOMEDICAL SCIENCES (Lecture 4h, course work 2h).
- O'Boyle G, Fox CR, Walden HR, Willet JD, Mavin ER, Hine DW, Palmer JM, Barker CE, Lamb CA, Ali S, Kirby JA. Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proceedings of the National Academy of Sciences 2012, 109(12), 4598-4603.
- Swan DJ, Kirby JA, Ali S. Post-Transplant Immunosuppression: Regulation of the Efflux of Allospecific Effector T Cells from Lymphoid Tissues. PLoS One 2012, 7(9), e45548.
- Ali S, O'Boyle G, Hepplewhite P, Tyler JR, Robertson H, Kirby JA. Therapy with Nonglycosaminoglycan-Binding Mutant CCL7: A Novel Strategy to Limit Allograft Inflammation. American Journal of Transplantation 2010, 10(1), 47-58.
- O'Boyle G, Mellor P, Kirby JA, Ali S. Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12. FASEB Journal 2009, 23(11), 3906-3916.
- Swan DJ, Kirby JA, Ali S. Vascular biology: the role of sphingosine 1-phosphate in both the resting state and inflammation. Journal of Cellular and Molecular Medicine 2010, 14(9), 2211-2222.
- Ali S, Jenkins Y, Kirkley M, Dagkalis A, Manivannan A, Crane IJ, Kirby JA. Leukocyte extravasation: An immunoregulatory role for α-L-Fucosidase?. Journal of Immunology 2008, 181(4), 2407-2413.
- Mavin E, Ahmed SS, O'Boyle G, Turner B, Douglass S, Collin M, Ali S, Dickinson A, Wang X-N. Regulatory T Cells Inhibit CD8+ T-Cell Tissue Invasion in Human Skin Graft-Versus-Host Reactions. Transplantation 2012, 94(5), 456-464.
- Douglass S, Ali S, Meeson AP, Browell D, Kirby JA. The role of FOXP3 in the development and metastatic spread of breast cancer. Cancer and Metastasis Reviews 2012, 31(3-4), 843-854.
- Naemi FMA, Ali S, Kirby JA. Antibody-mediated allograft rejection: The emerging role of endothelial cell signalling and transcription factors. Transplantation Immunology 2011, 25(2-3), 96-103.
- Bradford L, Marshall H, Robertson H, Kirby JA, Graham G, Ali S, O'Boyle G. Cardiac Allograft Rejection: Examination of the Expression and Function of the Decoy Chemokine Receptor D6. Transplantation 2010, 89(11), 1411-1416.
- Nilsson J, Ali S, Harvey I, Kirby J, Meeson A. Stem cell therapy: a role for CXCR4 in homing bone marrow side population cells to areas of myocardial damage. International Journal of Cardiology 2010, 145(3), 554-555.
- Newton P, O'Boyle G, Jenkins Y, Ali S, Kirby JA. T cell extravasation: Demonstration of synergy between activation of CXCR3 and the T cell receptor. Molecular Immunology 2009, 47(2-3), 485-492.
- Al-Hamidi A, Pekalski M, Robertson H, Ali S, Kirby JA. Renal allograft rejection: The contribution of chemokines to the adhesion and retention of αE(CD103)β7 integrin-expressing intratubular T cells. Molecular Immunology 2008, 45(15), 4000-4007.
- Ali S, O'Boyle G, Mellor P, Kirby JA. An apparent paradox: Chemokine receptor agonists can be used for anti-inflammatory therapy. Molecular Immunology 2007, 44(7), 1477-1482.
- O'Boyle G, Brain JG, Kirby JA, Ali S. Chemokine-mediated inflammation: Identification of a possible regulatory role for CCR2. Molecular Immunology 2007, 44(8), 1954-1963.
- Ali S, Lazennec G. Chemokines: Novel targets for breast cancer metastasis. Cancer and Metastasis Reviews 2007, 26(3-4), 401-420.
- Harvey, J., Mellor, P., Eldaly, H., Lennard, T.W.J., Kirby, J., Ali, S. Inhibition of CXCR4-mediated breast cancer metastasis: A potential role for heparinoids?. Clinical Cancer Research 2007, 13(5), 1562-1570.
- Mellor, P., Harvey, J., Murphy, K, Pye, D., O'Boyle, G, Lennard, T.W.J., Kirby, J., Ali, S. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. British Journal of Cancer 2007, 97(6), 761-768.
- Ali S, Robertson H, Wain JH, Isaacs JD, Malik G, Kirby JA. A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. Journal of Immunology 2005, 175(2), 1257-1266.
- Ali S, Malik G, Burns A, Robertson H, Kirby JA. Renal transplantation: Examination of the regulation of chemokine binding during acute rejection. Transplantation 2005, 79(6), 672-679.
- Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA. Chronic Renal Allograft Dysfunction: The Role of T Cell-Mediated Tubular Epithelial to Mesenchymal Cell Transition. Journal of the American Society of Nephrology 2004, 15(2), 390-397.
- Hardy LA, Booth TA, Lau EK, Handel TM, Ali S, Kirby JA. Examination of MCP-1 (CCL2) partitioning and presentation during transendothelial leukocyte migration. Laboratory Investigation 2004, 84(1), 81-90.
- Dowsland, M., Harvey, J., Lennard, T.W.J., Kirby, J.A., Ali, S. Chemokines and breast cancer: A gateway to revolutionary targeted cancer treatments?. Current Medicinal Chemistry 2003, 10(7), 579-592.
- Carter N, Ali S, Kirby JA. Endothelial inflammation: the role of differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. Journal of Cell Science 2003, 116(7), 3591.
- Carter NM, Ali S, Kirby JA. Endothelial inflammation: The role of differential expression of N-deacetylease/N-sulphotransferase enzymes in alteration of the immunological properties of heparan sulphate. Journal of Cell Science 2003, 116(17), 3591-3600.
- Rao JN, Clark SC, Ali S, Kirby J, Flecknell PA, Dark JH. Improvements in lung compliance after pulmonary transplantation: Correlation with interleukin 8 expression. European Journal of Cardio-thoracic Surgery 2003, 23(4), 497-502.
- Ali S, Hardy LA, Kirby JA. Transplant immunobiology: A crucial role for heparan sulfate glycosaminoglycans?. Transplantation 2003, 75(11), 1773-1782.
- Wong WK, Robertson H, Carroll H, Ali S, Kirby JA. Tubulitis in renal allograft rejection: role of TGFb and IL-15 in development and maintenance of CD103+T cells. Transplantation 2003, 75(4), 505-514.
- Ali S, Fritchley SJ, Chaffey BT, Kirby JA. Contribution of the putative heparan sulfate-binding motif BBXB of RANTES to transendothelial migration. Glycobiology 2002, 12(9), 535-543.
- Wain JH, Kirby JA, Ali S. Leucocyte chemotaxis: Examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by Monocyte Chemoattractant Proteins-1, -2, -3 and -4. Clinical and Experimental Immunology 2002, 127(3), 436-444.
- Carroll HP, Ali S, Kirby JA. Accelerating the induction of Fas-mediated T cell apoptosis: A strategy for transplant tolerance?. Clinical and Experimental Immunology 2001, 126(3), 589-597.
- Ali S, Palmer ACV, Fritchley SJ, Maley Y, Kirby JA. Multimerization of monocyte chemoattractant protein-1 is not required for glycosaminoglycan-dependent transendothelial chemotaxis. Biochemical Journal 2001, 358(3), 737-745.
- Ali S, Palmer ACV, Banerjee B, Fritchley SJ, Kirby JA. Examination of the function of RANTES, MIP-1α, and MIP-1β following interaction with heparin-like glycosaminoglycans. Journal of Biological Chemistry 2000, 275(16), 11721-11727.
- Naemi FMA, Carter V, Kirby JA, Ali S. Anti-Donor HLA Class I Antibodies: Pathways to Endothelial Cell Activation and Cell-Mediated Allograft Rejection. Transplantation 2013, 96(3), 258-266.
- O'Boyle G, Ali S, Kirby JA. Comment on "CXCL19 causes heterologous desensitization of CXCL12-mediated memory T cell activation". Journal of Immunology 2013, 191(2), 525.
- Willet JDP, Pichitsiri W, Jenkinson SE, Brain JG, Wood K, Alhasan AA, Spielhofer J, Robertson H, Ali S, Kirby JA. Kidney transplantation: analysis of the expression and T cell-mediated activation of latent TGF-β. Journal of Leukocyte Biology 2013, 93(4), 471-478.
- Pekalski M, Jenkinson SE, Willet JDP, Poyner EFM, Alhamidi AH, Robertson H, Ali S, Kirby JA. Renal allograft rejection: Examination of delayed differentiation of Treg and Th17 effector T cells. Immunobiology 2013, 218(3), 303-310.
- O'Boyle G, Ali S, Kirby JA. Chemokines in transplantation: what can atypical receptors teach us about anti-inflammatory therapy?. Transplantation Reviews 2011, 25(4), 136-144.
- Shaharuddin B, Ahmad S, Meeson A, Ali S. Immunological Properties of Ocular Surface and Importance of Limbal Stem Cells for Transplantation. Stem Cells Translational Medicine 2013, 2(8), 614-624.
- Ferreras L, Sheerin NS, Kirby J, Ali S. Mechanisms of renal graft chronic injury and progression to interstitial fibrosis. Current Transplantation Reports 2015. In Press.
- Douglass A, Meeson AP, Overbeck-Zubrzycka D, Brain JG, Bennett MR, Lamb CA, Lennard TWJ, Browell D, Ali S, Kirby JA. Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12. The Journal of Pathology 2014, 234(1), 74-85.
- Shaharuddin B, Harvey I, Ahmad S, Ali S, Meeson A. Characterisation of Human Limbal Side Population Cells Isolated Using an Optimised Protocol From an Immortalised Epithelial Cell Line and Primary Limbal Cultures. Stem Cell Reviews and Reports 2014, 10(2), 240-250.
- Alhasan AA, Spielhofer J, Kusche-Gullberg M, Kirby JA, Ali S. Role of 6-O-Sulfated Heparan Sulfate in Chronic Renal Fibrosis. Journal of Biological Chemistry 2014, 289(29), 20295-20306.
- Ladak SS, Ali S, Ward C. The potential role of miRNA-200b in the development of Bronchiolitis obliterans syndrome. In: British Society for Immunology Annual Congress. 2014, Brighton, UK: Wiley-Blackwell Publishing.
- Barker CE, Ali S, O'Boyle G, Kirby JA. Transplantation and inflammation: implications for the modification of chemokine function. Immunology 2014, 143(2), 138-145.
- Ali S, Sheerin NS. Biomarkers of acute injury: predicting the long-term outcome after transplantation. Kidney International 2013, 84(6), 1072-1074.
- Douglass S, Ali S, Meeson AP, Browell D, Kirby JA. Erratum to: The role of FOXP3 in the development and metastatic spread of breast cancer (vol 31, pg 843, 2012). Cancer and Metastasis Reviews 2013, 32(3-4), 763-763.
- Saleki M, Colgin N, Kirby JA, Cobb SL, Ali S. Evaluation of two cyclic di-peptides as inhibitors of CCL2 induced chemotaxis. MedChemComm 2013, 4(5), 860-864.
- Gschwandtner M, Trinker MU, Hecher B, Adage T, Ali S, Kungl AJ. Glycosaminoglycan silencing by engineered CXCL12 variants. FEBS Letters 2015, 589(19), 2819-2824.
- Shaharuddin B, Ahmad S, MdLatar N, Ali S, Meeson A. A Human Corneal Epithelial Cell Line Model for LimbalStem Cell Biology and Limbal Immunobiology. Stem Cells Translational Medicine 2016, (ePub ahead of Print).
- Dang TS, Willet JDP, Griffin HR, Morgan NV, O'Boyle G, Arkwright PD, Hughes SM, Abinun M, Tee LJ, Barge D, Engelhardt KR, Jackson M, Cant AJ, Maher ER, Koref MS, Reynard LN, Ali S, Hambleton S. Erratum to: Defective Leukocyte Adhesion and Chemotaxis Contributes to Combined Immunodeficiency in Humans with Autosomal Recessive MST1 Deficiency (vol 36, pg 117, 2016). Journal of Clinical Immunology 2016, 36(3), 336-337.
- Shaharuddin B, Osei-Bempong C, Ahmad S, Rooney P, Ali S, Oldershaw R, Meeson A. Human limbal mesenchymal stem cells express ABCB5 and can grow on amniotic membrane. Regenerative Medicine 2016, 11(3), 273-286.
- Ladak SS, Ward C, Ali S. The potential role of microRNAs in lung allograft rejection. Journal of Heart and Lung Transplantation 2016, 35(5), 550-9.
- del Barrio ID, Kirby J, Ali S. The Role of Chemokine and Glycosaminoglycan Interaction in Chemokine-Mediated Migration In Vitro and In Vivo. Methods in Enzymolgy 2016, 570, 309-333.
- Andreasson A, Karamanou D, Gillespie C, Borthwick L, Jiwa K, Henderson P, Ozalp F, Butt T, Clark SC, Pauli H, Corris PA, Ali S, Dark JH, Fisher AJ. Treating Donor Lung Inflammation by Blocking Interleukin-1B-An In Vitro Therapy Testing Platform for Ex Vivo Lung Perfusion. In: International Society for Heart and Lung Transplantation 36th Annual Meeting and Scientific Sessions. 2016, Washington, DC: Elsevier.
- Ladak S, Ward C, Ali S. MicroRNA-200b represses TGF-β1 induced EMT in BEAS-2B and primary bronchial epithelial cells. In: British Thoracic Society. 2015, London, UK: BMJ Publishing Group.
- Figueiredo GS, Lako M, Ali S, Figueiredo FC. Molecular analysis of inflammation in pannus tissue from patients with total limbal stem cell deficiency by quantitative real time PCR. In: MCLOSA 22nd Annual Scientific Meeting. 2015, London, UK: Association for Research in Vision and Ophthalmology.
- Shaharuddin B, Ahmad S, Ali S, Meeson A. Limbal side population cells; a future treatment for limbal stem cell deficiency. In: Tissue Engineering & Regenerative Medicine International Society, European Chapter Meeting. 2014, Genova, Italy: John Wiley & Sons, Inc.
- Thompson S, Redgrave R, Kirby J, Arthur H, Ali S. Modulation of wound healing post-myocardial infarction. In: British Society for Immunology Annual Congress. 2014, Brighton, UK: Wiley-Blackwell.
- Shaharuddin B, Ahmad S, Ali S, Meeson A. Limbal Side Population cells: a future treatment for limbal stem cell deficiency. Regenerative Medicine 2013, 8(3), 319-331.